Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Phase 2 Unknown
40 enrolled
AL3818
Phase 3 Unknown
294 enrolled
SELENIUM
Phase 3 Unknown
68 enrolled
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
Phase 2 Unknown
20 enrolled
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
Phase 3 Unknown
1,157 enrolled 15 charts
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 3 Unknown
637 enrolled 18 charts
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Unknown
290 enrolled
MITO25
Phase 1/2 Unknown
290 enrolled
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Phase 1 Unknown
46 enrolled
ROCOCO
Phase 3 Unknown
298 enrolled
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Phase 2 Unknown
100 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Unknown
30 enrolled
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Unknown
88 enrolled
ICON8
Phase 3 Unknown
1,485 enrolled
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2 Unknown
314 enrolled
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
Phase 2 Unknown
100 enrolled